Imbruvica Patent Protection
44 patents · Pharmacyclics LLC, AbbVie Inc.
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 8476284 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 8497277 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 8952015 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 8703780 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 8735403 | Drug substance & product patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 7514444 | Drug substance & product patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 8957079 | Drug substance & product patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 9181257 | Drug substance & product patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 8697711 | Drug substance & product patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 8754091 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Jun 28, 2027 | 1.0y left |
| 8563563 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Oct 26, 2027 | 1.3y left |
| 8008309 | Drug substance & product patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | May 13, 2028 | 1.9y left |
| 11672803 | Orange Book listed patent | Pharmacyclics LLC | Jun 3, 2031 | 4.9y left |
| 9125889 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 8999999 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 9801881 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 10004746 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 10016435 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 9801883 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 10478439 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 10751342 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 8754090 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 9814721 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 10653696 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2031 | 5.4y left |
| 10961251 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2033 | 7.4y left |
| 10106548 | Drug substance & product patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2033 | 7.4y left |
| 10752634 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2033 | 7.4y left |
| 9713617 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2033 | 7.4y left |
| 10294231 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2033 | 7.4y left |
| 9725455 | Drug substance (composition of matter) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2033 | 7.4y left |
| 10294232 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2033 | 7.4y left |
| 10125140 | Drug substance & product patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Dec 3, 2033 | 7.4y left |
| 9540382 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Feb 18, 2034 | 7.7y left |
| 9296753 | Drug substance & product patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Apr 30, 2034 | 7.8y left |
| 9795604 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Apr 24, 2035 | 8.8y left |
| 10463668 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Apr 24, 2035 | 8.8y left |
| 10695350 | Orange Book listed patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Apr 24, 2035 | 8.8y left |
| 12551448 | Drug product (formulation / method-of-use) patent | Pharmacyclics LLC | Mar 3, 2036 | 9.7y left |
| 12364698 | Drug product (formulation / method-of-use) patent | Pharmacyclics LLC | Apr 6, 2036 | 9.8y left |
| 10010507 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Sep 3, 2036 | 10.2y left |
| 10213386 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Sep 3, 2036 | 10.2y left |
| 9655857 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Sep 3, 2036 | 10.2y left |
| 10828259 | Drug product (formulation / method-of-use) patent (incl. pediatric exclusivity extension) | Pharmacyclics LLC | Sep 3, 2036 | 10.2y left |
| 12201690 | Drug product (formulation / method-of-use) patent | Pharmacyclics LLC | Jun 14, 2039 | 13.0y left |
Related Drug Patent Expirations
45 patents · earliest expires 2031 · AbbVie Inc.
0 patents · AbbVie Inc.
0 patents · AbbVie Inc.
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
6 patents · earliest expires 2027 · Novartis AG
3 patents · earliest expires 2027 · Pfizer Inc.
Imbruvica is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Imbruvica is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.